PSI™ Applied to Autoimmune Progression and Precise Therapeutic Targeting

Application Highlight

PSI™ Applied to Autoimmune Progression and Precise Therapeutic Targeting

Learn how PSI can help you characterize critical functional subsets of innate immune cells in multiple sclerosis patients to understand novel targets and advance therapy development.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this Application Highlight we discuss:

How Polyfunctional Strength Index (PSI) can be used to assess cytokine secretion of single innate immune cell

Demonstrate the value of PSI to reveal functional heterogeneity of single innate immune cells

Show that by detecting highly dysfunctional cell subsets, PSI can lead to the unique detection of key patient differences in autoimmune progression

Demonstrate how these differences can reveal critical therapeutic insight and novel targets

App_Note_PSI_and_Autoimmune_Progression_IsoPlexis_1

App_Note_PSI_and_Autoimmune_Progression_IsoPlexis_2

App_Note_PSI_and_Autoimmune_Progression_IsoPlexis_3

A Deeper Look

More about this Application Highlight

Role of Innate Immunity in Multiple Sclerosis Pathogenesis Requires Further Understanding

MS is a complex disease that varies dramatically between individuals, and MS patients benefit from early diagnosis and a multifaceted therapeutic approach that slows disease progression and tries to reduce the number and severity of attacks.

Download this App Highlight to learn how IsoPlexis was used to identify a pathologically and therapeutically relevant Toll-like receptor (TLR) previously uncharacterized in MS and to prove the hypothesis that MS patients have a deficiency in innate immune regulation leading to hyper-responsiveness to TLR2 stimulation.

Get the Application Highlight

Back to the Top